1811TiP SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with SCLC, LCNEC and EP-NEC known to express DLL3
Year: 2024
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, Medpace, Array BioPharma, Regeneron Pharmaceuticals, Taiho Pharmaceutical, Jazz Pharmaceuticals, Constellation Pharmaceuticals, Boehringer Ingelheim Japan, Incyte, Compass Therapeutics, Moderna, Coherus Biosciences, Eisai, Astellas Pharma, Shionogi, Otsuka Pharmaceutical, Japanese Society of Medical Oncology, Ono Pharmaceutical, Betta Pharmaceuticals, Genentech, EMD Serono, Novartis Pharma, Pfizer Japan, Chugai Pharmaceutical, Eli Lilly Japan, Pharmacyclics, Bayer Yakuhin, Daiichi Sankyo Europe
OpenAlex ID: W4402566035